Dementia expert says evidence behind Biogen Alzheimer's drug 'wasn't sufficient' for FDA approvalCNBC • 06/08/21
Approval of Biogen's drug for Alzheimer's disease may ease path for others such as Athira PharmaGeekWire • 06/07/21
The Ratings Game: Biogen stock rockets to 6-year high after Alzheimer's drug gets FDA OKMarket Watch • 06/07/21
Biogen CEO says $56,000 annually for Alzheimer's drug is 'fair,' promises not to hike price for at least 4 yearsCNBC • 06/07/21
Biogen soars 64% after FDA approves first new Alzheimer's drug in 18 years (BIIB)Business Insider • 06/07/21
Biogen and Eisai launch multiple initiatives to help patients with Alzheimer's disease access ADUHELM™GlobeNewsWire • 06/07/21
FDA grants accelerated approval for ADUHELM™ as the first and only Alzheimer's disease treatment to address a defining pathology of the diseaseGlobeNewsWire • 06/07/21
The Wall Street Journal: FDA approves Biogen's Alzheimer's drug, the first to slow the diseaseMarket Watch • 06/07/21